Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
The press release announces the proposed establishment of Alif Maritec, a wholly owned subsidiary focused on marine security and intelligent maritime infrastructure. This represents a material strategic expansion of Robo.ai's business footprint through a new operating platform within its Alif Holding industrial group. While the subsidiary has not yet been formally established, the announcement of this planned business line expansion—described as "the next step in expanding our business footprint" and part of the company's "Building Intelligent Industries" strategy—constitutes a material operational development that would affect a reasonable investor's assessment of the company's growth trajectory and business diversification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
This press release announces RADCOM's selection by VNPT, a major Tier-1 telecom operator with over 30 million subscribers, to provide AI-native cloud-native service assurance following a competitive RFP process. The disclosure describes this as "a strategically important reference win for RADCOM in the Asia-Pacific region" and notes it was one of three contracts secured following Q2 2026. While not a discrete M&A transaction, this is a material customer win and contract award that would affect investor assessment of the company's market position and revenue prospects in a key geographic region.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
OceanaGold announces submission of a permit application (Macraes Phase 4 Project) to extend mine life at its Macraes operation from 2032 to the late 2030s, supported by exploration drilling results and technical studies. This is a material operational and strategic milestone—extending mine life is fundamental to the registrant's long-term production profile and value creation—but does not fit the specific event types (M&A, earnings, impairment, etc.). The disclosure is clearly operational/strategic in nature, making operational_other the appropriate classification.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.4
ZenaTech announced completion of an initial prototype and commencement of field testing for the IQ Octo, a new autonomous drone designed for precision agriculture spraying and seeding, representing a material product development milestone that advances the company's Drone as a Service business into a high-growth market segment.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.5
ZenaTech announced a strategic franchise business plan for drone-based power washing services, leveraging its June 2026 acquisition of Green Earth Powerwashing, with expansion goals across Florida and nationally, representing a material operational and strategic development that affects investor assessment of the company's growth trajectory and business execution.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The NJBPU approval of a $68 million annualized revenue increase for New Jersey American Water's general rate case is a material operational and regulatory milestone. While this is a favorable regulatory outcome supporting $1.4 billion in infrastructure investments, it does not fit neatly into the specific financial event categories (not a debt issuance, impairment, or covenant breach) nor governance categories. The event is clearly operational/regulatory in nature—a rate approval that affects the company's revenue base and capital investment program—making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
The filing discloses completion of the last-subject-dosed milestone in a Phase 1b clinical trial for CDI-988, a novel antiviral candidate for norovirus. This represents a material operational and clinical development milestone for a clinical-stage biotech company, with preliminary efficacy results expected in late 2026 or early 2027. While this is a positive clinical progress event rather than a specific named event type (earnings, M&A, impairment, etc.), it is clearly material to investors' assessment of the company's pipeline advancement and would affect the total mix of information available.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
NextTrip announced the international expansion of its JOURNY TV travel entertainment channels to LG Smart TVs across 20 international markets, extending its global media distribution footprint to more than a dozen major platforms across approximately 80 countries with estimated reach of 250 million viewers. This represents a significant operational and strategic business milestone—a material distribution expansion for the company's core media platform—but does not fit the specific categories of M&A activity, debt issuance, earnings release, or other named event types. The disclosure centers on a platform partnership and content distribution expansion rather than a discrete financial or governance event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99.1
Santacruz Silver announced receipt of conditional approval from the Toronto Stock Exchange to graduate its listing from TSX Venture Exchange to the main TSX board. This is a material operational and strategic milestone — the company will voluntarily delist from TSX.V and commence trading on TSX under symbol "SCZ" — that enhances market visibility and access to capital markets. While not a discrete M&A transaction, debt issuance, or other named event type, this listing upgrade is a significant corporate development affecting investor access and the company's market profile.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
The filing discloses submission of a 510(k) premarket notification to the FDA for the Intelligent Fingerprinting Drug Screening System seeking regulatory clearance for codeine detection. This is a material regulatory milestone for a medical device company, representing a key step toward U.S. market entry in a multi-billion-dollar drug screening market. While not fitting a specific named event type, this is clearly an operational/strategic business event—a regulatory submission milestone—that would affect a reasonable investor's assessment of the company's commercialization progress and market opportunity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
The filing discloses results from Hycroft Mining's 2025-2026 Exploration Drill Program at the Hycroft Mine, reporting significant drill intercepts from the Vortex and Brimstone high-grade silver systems. The press release highlights substantial mineralization grades (e.g., 30.5 meters at 780.53 g/t silver, 5.5 meters at 1,345.27 g/t silver) and indicates these discoveries represent "a significant value driver for the Hycroft Mine." This is an operational/strategic milestone—exploration results that advance the company's development strategy—rather than a financial event (no earnings or capital transaction), governance event, or legal matter. The materiality stems from the company's explicit characterization of these high-grade systems as value drivers and the implications for future mine development.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.1
Trinity Biotech's Trinovium subsidiary has signed a contract with Red Team Investments to supply advanced liquid cooling solutions for AI data center infrastructure, establishing a commercial pilot program with paid product supply. This represents a material operational and strategic milestone—entry into a new market segment (data center cooling) with a committed customer and real-world validation pathway. While not a discrete M&A transaction, debt issuance, or earnings event, it is a significant business development that would affect a reasonable investor's assessment of the company's growth prospects and diversification into the rapidly expanding AI infrastructure market.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-09
EX-99
This press release announces an updated Preliminary Economic Assessment (PEA) for the Boumadine Project, a development-stage polymetallic mining project. The 2026 PEA represents a material operational and strategic milestone, showing significantly improved project economics (after-tax NPV doubled to $3.5B with 93% IRR), extended mine life from 11 to 14 years, and higher silver production. While the document contains financial projections and economic analysis, it is fundamentally a technical and operational disclosure about the advancement of a major development project rather than a discrete financial event (like debt issuance or M&A), making it an operational milestone that would affect a reasonable investor's assessment of the company's strategic positioning and future production capacity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
Centrus announced a definitive multi-year contract with Radiant Industries to supply high-assay low-enriched uranium (HALEU) for Kaleidos microreactors, with deliveries beginning before the end of the decade. The agreement includes prepayments to Centrus to support its domestic enrichment capacity expansion. This is a material commercial contract that adds a significant customer to Centrus' backlog and advances its strategic positioning in the emerging microreactor market, but it does not fit the specific categories of M&A activity, debt issuance, or other defined financial/operational events—making it an operational business development matter best classified as operational_other.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The disclosure reports receipt of a $35-$40 million order from an existing North America customer for Aviat Networks' subsidiary. This is a material operational/commercial event reflecting significant new business activity, but it does not fit a specific named category (not M&A, not a contract milestone with regulatory significance, not a partnership announcement). The materiality threshold is met given the order size relative to typical mid-cap telecom equipment vendor revenues, and the disclosure is made under Regulation FD, indicating management's view of investor relevance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Stewards, Inc. received approval from Nasdaq to list its common stock on the Nasdaq Capital Market, with trading expected to commence on September 10, 2026, under ticker symbol "SWRD." This represents a significant operational and strategic milestone—an uplisting from OTC Markets to a major national exchange—that would materially affect investor visibility, liquidity, and the company's access to capital markets. While not a traditional M&A transaction, debt issuance, or earnings event, this listing approval is a material operational/strategic development that enhances the company's market profile and capital-raising capacity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The disclosure announces a hosting and operations agreement between Tianci International and BTC Digital Ltd. for cryptocurrency mining equipment deployment and management. This is a material operational and strategic event—the company is executing on its previously disclosed cryptocurrency mining business expansion by establishing a service framework with a third-party provider. While the agreement itself is not a merger, acquisition, or debt issuance, it represents a significant operational milestone in the company's stated pivot into digital asset and computing infrastructure sectors, affecting the total mix of information available to investors about the company's business strategy and execution capability.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
Serina announced that its Independent Safety Monitoring Committee has recommended advancement of SER-252 from Cohort 1 to Cohort 2 in a Phase 1b registrational study for advanced Parkinson's disease, with positive preliminary pharmacokinetic and exploratory clinical observations. This is a material clinical development milestone for a clinical-stage biotech company's lead program, but does not fit the specific event types (earnings, M&A, litigation, etc.); it is a significant operational/strategic advancement in the drug development pipeline that would affect investor assessment of the company's progress.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The disclosure reports that the FDA has granted Anavex's request for a meeting to discuss inclusion of pediatric patients in its Phase 3 clinical trial for ANAVEX 2-73 in Rett syndrome. This is a material regulatory milestone in the company's clinical development pipeline for a lead candidate, affecting the scope and timeline of a pivotal trial. While not a specific named event type, this is clearly an operational/clinical development matter material to investors assessing the company's drug development progress.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-09
EX-99.2
Micware presented its strategic direction and FY2026 audited financial results (revenue $140.3M, gross margin 36.8%, net income $15.6M), including organizational restructuring with the renaming of Micware Navigations to Micware Spacia, consolidation of automotive operations, and capital allocation from IPO proceeds toward two growth pillars: micAuto-PF and DynaPlanet. This strategic business disclosure is material to investors' assessment of the company's direction and execution capability.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 7.01
RXO disclosed preliminary third-quarter 2026 operating metrics via press release, highlighting that "truckload gross profit per load increased by more than 10 percent in August when compared to July, which was better than the outlook provided on the company's second-quarter earnings conference call." This is a material operational update on business performance metrics ahead of formal earnings release, but it is not a complete earnings release (results are explicitly noted as "not completed" and "subject to quarter-end closing procedures"). The disclosure centers on operational performance—gross profit per load, volume trends, and spot market activity—rather than final financial results, making operational_other the most precise classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-09
Item 8.01
The filing discloses a partial clinical hold issued by the FDA on September 4, 2026, pausing new patient enrollment in the BHV-7000 program pending additional nonclinical studies of a metabolite with uncertain human safety significance. While the company emphasizes that dosing continues for already-enrolled patients and that BHV7000-303 (a pivotal trial) remains on track for topline data in H2 2026, the regulatory pause on new enrollment represents a material operational setback to the clinical development program. This is a regulatory/operational event that does not fit the specific categories of restatement, auditor change, going concern, material impairment, delisting, bankruptcy, covenant breach, cybersecurity incident, dilutive issuance, material litigation, or debt issuance, making operational_other the most appropriate classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
Smithfield issued a press release updating its third-quarter 2026 outlook ahead of a conference appearance, citing "persistent Fresh Pork industry processing margin compression and lower hog prices" as drivers of revised guidance. The company lowered Fresh Pork segment expectations to an operating loss of $70–$90 million while adjusting Hog Production guidance downward, though reaffirming Packaged Meats. This is a material operational and market-driven guidance revision that would affect investor assessment of near-term profitability, but it does not constitute an earnings release (which reports actual results) nor a specific financial event like debt issuance or impairment. The disclosure is operational in nature—reflecting external commodity market dynamics and their impact on segment performance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 1.01
This disclosure concerns an amendment to a material development and host community agreement for the American Place casino facility in Waukegan, Illinois. The amendment extends the construction completion date to February 17, 2029, permits retention of a temporary casino structure for five years post-opening, and revises project details. While this is a material definitive agreement amendment affecting a significant capital project, it does not fit the specific categories of M&A activity, debt issuance, or other named financial/legal events—it is primarily an operational/strategic project milestone adjustment disclosed under Item 1.01.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Southern Company Gas' subsidiary Nicor Gas entered into a Stipulation and Settlement on September 8, 2026, to resolve a general base rate case with the Illinois Commerce Commission. The settlement provides for an $82 million annual base rate revenue increase with a 9.48% return on equity, subject to Illinois Commission approval by December 7, 2026. This is a material regulatory and operational event affecting the company's rate structure and revenue, but does not fit the specific categories of debt issuance, dividend distribution, workforce reduction, or other named financial/operational types—it is a regulatory settlement with significant business implications.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release announces the successful energization of the Treaty Creek Terminal, a key infrastructure milestone for the KSM Project. The terminal represents a material operational achievement in the development of the Company's principal asset, providing access to reliable hydroelectric power that reduces operating costs and carbon footprint. While not fitting a discrete named category, this is clearly a material operational/strategic milestone that would affect a reasonable investor's assessment of project development progress.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This exhibit is a press release announcing drilling results at the Span Prospect, a mineral exploration project. The company reports discovery of a 40.4m intercept of 2.05 g/t Au and other mineralized zones, representing an operational milestone in exploration activity. While the results are positive and could support future resource expansion, this is an exploration announcement rather than a discrete material event (M&A, impairment, covenant breach, etc.). The disclosure is material because it reports significant exploration success that could affect investor assessment of the company's asset value and development potential.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Gold X2 announces commencement of trading on NYSE American under ticker "AUXX" following approval to list. This is a material operational and capital-markets milestone — a listing event that expands the company's investor base and market visibility — but does not fit the specific event-type taxonomy (no dedicated category for exchange listing or transfer of listing). The disclosure is clearly operational/strategic in nature and material to investors, warranting `operational_other` rather than `other_material` since the domain is clear.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This exhibit is an operational update on the Company's Indonesia growth platform and product development initiatives, including securing a clinic premises in Jakarta, finalizing subscription pricing, and identifying cosmetic product candidates with manufacturing partners INVITRX and PARVA. The disclosure describes strategic business progress on multiple fronts (clinic site development, product formulation, manufacturing partnerships) that would affect a reasonable investor's assessment of the Company's execution on previously announced initiatives, but does not fit a specific named event type such as M&A, earnings, or material litigation.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
Belite Bio announced submission of a New Drug Application (NDA) to Japan's Ministry of Health, Labour, and Welfare for tinlarebant under the Sakigake expedited designation system, alongside FDA acceptance of a U.S. NDA with Priority Review. This is a material regulatory milestone for a clinical-stage company's lead candidate, representing significant progress toward potential first-ever approval for Stargardt Disease Type 1. The event is operational/strategic (regulatory advancement) rather than a discrete financial, governance, or legal event, and does not fit the specific categories of earnings, M&A, or other named types.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 7.01
United Community Banks announced a strategic balance sheet repositioning involving the sale of ~$2.6 billion in lower-yielding securities (generating an estimated $300 million pre-tax loss), redeployment into higher-yielding assets, and completion of the Navitas sale ($2.0 billion proceeds, $64 million gain). While this involves financial transactions (securities sales, debt-like repositioning), the core disclosure centers on a strategic operational and portfolio management initiative designed to reduce interest rate risk, improve earnings, and fund organic growth—not a discrete financial event like debt issuance, impairment, or restatement. The Item 7.01 Regulation FD Disclosure classification and the emphasis on strategic initiatives and business transformation support an operational_other classification.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Structure Therapeutics announced positive topline clinical trial results for two lead product candidates: ACCG-2671 (Phase 1/2a SAD results showing ~6-day half-life, 3.3% body weight loss, no serious adverse events) and aleniglipron (72-week ACCESS OLE results showing up to 16.2% body weight loss with improved tolerability). These material clinical milestones represent significant operational and strategic progress for the clinical-stage biopharmaceutical company's pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
Orchestra BioMed furnished a corporate overview slide presentation describing its product pipeline, clinical evidence, partnership model, and strategic capital backing from partners including Medtronic and Terumo. The presentation highlights two pivotal-stage programs (AVIM Therapy and Virtue SAB), clinical trial progress, and upcoming catalysts including potential FDA approval and trial enrollment completion, with capital runway disclosed through 2027.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This press release announces a strategic partnership between Nebius and Palantir Technologies in which Palantir names Nebius its "preferred sovereign AI infrastructure partner" and will integrate Nebius compute and inference capabilities into Palantir's enterprise platform. The partnership involves bringing new AI capacity online and enabling Palantir customers to access Nebius infrastructure. This is a material operational and strategic business event—a significant partnership with a major technology company that expands Nebius's addressable market and revenue opportunities—but does not fit the specific categories of M&A activity, debt issuance, or other defined event types. It is clearly operational/strategic in nature rather than financial, governance, or legal.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 7.01
United Community Banks disclosed a "strategic balance sheet repositioning" involving multiple material operational and financial initiatives: the sale of Navitas (a non-core lending platform) for $2 billion in cash with a $68 million pretax gain; a major portfolio restructure involving reclassification of $2.6 billion in securities from held-to-maturity to available-for-sale status and realization of embedded losses; and strategic reinvestment in core banking operations including hiring 42 net new revenue producers and completing the Peach State acquisition. While this disclosure contains elements of M&A activity (Navitas sale, Peach State acquisition) and financial repositioning, the overarching narrative centers on a comprehensive operational and strategic restructuring to simplify the business, reduce risk, and reposition for growth—making it primarily an operational strategic initiative rather than a single discrete event type.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
ArcBest is providing preliminary third-quarter 2026 business trends and operating metrics for its two segments (Asset-Based and Asset-Light), including revenue per day, tonnage, shipments, and operating income guidance. This is a business update disclosing operational performance trends and forward-looking guidance that would inform investors about current business momentum and near-term expectations, but it is not a formal earnings release (which would typically be Item 2.02 with a press release exhibit). The disclosure is material to investors assessing operational performance and trends, but the event type does not fit the specific categories of earnings_release, ma_activity, or other named types—it is a strategic operational disclosure of preliminary results and guidance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Ocugen disclosed material clinical and regulatory progress for its gene therapy pipeline, including initiation of Phase 3 dosing for OCU410 in geographic atrophy following FDA alignment and RMAT designation, and a Data Monitoring Committee recommendation to continue the OCU410ST Phase 2/3 trial for Stargardt disease. The company also posted a corporate presentation detailing clinical trial data, regulatory milestones, and market potential for three programs (OCU400, OCU410ST, and OCU410).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-08
EX-99.1
This news release announces a major operational milestone: first copper-gold concentrate production at the Skouries Project in Greece on September 8, 2026, with commercial production expected in Q4 2026. The release emphasizes this as "a defining moment for Eldorado" and describes Skouries as "transformational" and "one of Europe's largest copper-gold projects." While not a discrete M&A event, earnings release, or executive change, this represents a material operational achievement—the transition from construction to production at a major new asset that is expected to transform the company into "a larger, more diversified precious metals and critical minerals producer with a stronger production base" and enhance "free cash flow generation." This would materially affect a reasonable investor's assessment of the company's operational trajectory and future cash generation capacity.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
The disclosure announces positive Phase 2 clinical trial results for mosliciguat in pulmonary hypertension associated with interstitial lung disease, including achievement of primary and secondary endpoints with statistically significant improvements in pulmonary vascular resistance (-56.3%), six-minute walk distance (+35.2m), and NT-proBNP reduction (-53.2%). The filing also announces initiation of a Phase 3 trial (PHrontier). This is a material clinical development milestone for a biopharmaceutical company's pipeline asset, representing significant progress toward potential regulatory approval and commercialization, though it does not fit neatly into the specific financial, governance, or legal event categories.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Brookfield announced selection by the Nuclear Liabilities Fund to manage a multi-decade investment mandate with an initial $1 billion commitment across Brookfield's infrastructure, energy, private equity, real estate, and credit strategies. This is a material business development—a significant new client relationship and investment mandate—but does not fit neatly into the specific event categories (not M&A, not a debt/equity issuance, not a restructuring). It is clearly operational/strategic in nature, representing a major institutional client win that would affect investor assessment of the registrant's business prospects and AUM growth.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
Novartis announced that its Phase III HARBOR study of del-desiran for myotonic dystrophy type 1 (DM1) failed to meet its primary endpoint of video hand opening time (vHOT), though secondary endpoints showed some clinical activity. This is a material clinical trial failure for an investigational therapy in Novartis's neuromuscular pipeline acquired through Avidity Biosciences. While the company maintains its 5-6% sales CAGR guidance and continues advancing other AOC therapies (del-zota and del-brax), the HARBOR failure represents a significant setback in a high-unmet-need indication and would affect investor assessment of the pipeline's value and development strategy.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces positive results of a Preliminary Economic Assessment (PEA) for the Franklin Project, a greenfield lithium extraction facility in East Texas. The disclosure presents material operational and strategic milestones—a $5.0 billion after-tax NPV, 24% IRR, 70,000 tpa production capacity, and upgraded mineral resources—that would affect a reasonable investor's assessment of the company's project pipeline and value creation potential. While not a discrete M&A transaction, earnings release, or governance event, this represents a significant operational/strategic development in project advancement that warrants classification as a material operational event.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This press release announces publication of peer-reviewed pilot study results showing 83.3% response rate and 50% remission rate for BrainsWay's Deep TMS technology in patients with depression and early-stage Alzheimer's disease, with measurable neurophysiological changes. While the study is preliminary and not FDA-cleared for Alzheimer's indication, the positive clinical findings and peer-reviewed publication represent a material operational/scientific milestone that would affect investor assessment of the company's product pipeline and clinical evidence base. This is not an earnings release (no financial results), but rather a clinical/product development milestone that is material to the company's strategic positioning.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-08
EX-99.1
This exhibit is an investor presentation disclosing AIR Global PLC's H1'2026 financial performance, strategic positioning, and forward guidance. The presentation covers resilient revenue growth (3.7% despite Strait of Hormuz disruption), Adjusted EBITDA performance ($71.7m, flat YoY), and medium-term outlook including low-single-digit FSM volume growth and high-single-digit EBITDA growth. While the document contains financial metrics and guidance, it is a strategic business presentation rather than a formal periodic financial report or earnings release press statement. The disclosure is material as it provides investors with updated operational performance, market positioning, and forward-looking guidance that would affect investment decisions.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Monte Rosa announced that its collaborator Novartis has initiated a Phase 2 clinical study for MRT-6160 (DDY391) in Sjögren's disease, triggering a $50 million milestone payment and eligibility for up to $2.1 billion in additional development, regulatory, and sales milestones under their global exclusive license agreement. This represents a material operational and strategic milestone validating the company's technology platform and demonstrating significant progress in its partnered pipeline.
View raw filing on EDGAR →
8-K
Operational Other
confidence 72%
filed 2026-09-08
Item 7.01
IonQ announced updated full-year 2026 financial guidance ($450–$460 million revenue) following its July 31, 2026 acquisition of SkyWater Technology. While the guidance itself resembles an earnings-release disclosure, the core event is the post-acquisition integration and combined operational outlook. The filing emphasizes "executing on a shared roadmap" and "immediate financial and operational strength of bringing IonQ and SkyWater together," signaling a strategic operational milestone rather than a routine earnings announcement. The guidance is material to investors assessing the combined entity's trajectory, but the primary disclosure centers on the operational and strategic implications of the completed M&A integration rather than quarterly/annual results alone.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
The disclosure announces FDA Breakthrough Therapy designation for DT120 ODT in major depressive disorder, following positive Phase 3 Emerge study results showing statistically significant efficacy (8.1-point placebo-adjusted MADRS improvement, p<0.0001). This is a material regulatory milestone that accelerates development and review of an innovative medicine for a serious condition with significant unmet need, but does not fit the specific operational categories (workforce reduction, material contract, partnership, product milestone). The event is clearly operational/strategic—a regulatory achievement that advances the company's lead program—rather than financial, governance, legal, or existential in nature.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Veru announced a strategic shift in its drug development pipeline: advancing sabizabulin into Phase 2b clinical trials for daraxonrasib-resistant metastatic pancreatic cancer based on new positive preclinical data, while discontinuing exploration of sabizabulin for atherosclerotic cardiovascular disease. This represents a material operational and strategic decision affecting the company's pipeline priorities and resource allocation, but does not fit the specific categories of M&A, impairment, litigation, or other defined event types. The decision is material to investors as it redirects development efforts toward a potentially significant oncology indication with unmet medical need.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 7.01
ASP Isotopes disclosed its inaugural Capital Markets Day event in London on September 8, 2026, where management outlined strategy across multiple business segments (nuclear medicine, electronics, helium/LNG, nuclear fuels) and provided operational updates on commercialization progress, including expected revenue growth from liquid helium production and stable isotope shipments, plus a long-term EBITDA target of $300 million by 2031. This is a strategic business communication disclosing material operational milestones and forward guidance, but does not fit the specific categories of earnings release, M&A, debt issuance, or other defined event types—making it an operational disclosure of strategic importance to investors.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-08
Item 8.01
Intellia announced FDA acceptance of a Biologics License Application (BLA) with Priority Review for lonvo-z, a CRISPR-based therapy for hereditary angioedema, with a PDUFA target date of March 10, 2027. This represents a material regulatory milestone in the drug development and commercialization pathway for the company's lead product candidate.
View raw filing on EDGAR →